市場調査レポート
商品コード
1519371
ポイントオブケア診断薬市場レポート:製品タイプ、プラットフォーム、処方形態、エンドユーザー、地域別、2024年~2032年Point-of-Care Diagnostics Market Report by Product Type, Platform, Prescription Mode, End-User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ポイントオブケア診断薬市場レポート:製品タイプ、プラットフォーム、処方形態、エンドユーザー、地域別、2024年~2032年 |
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2~3営業日
|
世界のポイントオブケア診断薬市場規模は2023年に492億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに995億米ドルに達し、2024年から2032年の間に7.9%の成長率(CAGR)を示すと予測しています。より迅速で利便性の高い診断ソリューションに対する需要の高まり、世界の感染症流行の高まり、技術および小型化の進歩が市場を牽引する主な要因の一例です。
市場の成長と規模世界のポイントオブケア診断薬市場は、大衆の間で様々な慢性疾患の発生が増加していることから、緩やかな成長を遂げています。
主な市場促進要因:主な要因:ポイントオブケア(POC)ツールの開発拡大、患者の予後改善のための個別化医療への注目の高まりなど。
主要市場動向:主な動向には、遠隔地でのヘルスケアサービス提供のための高度な検査ソリューションやポータブルPOC検査システム開発のための研究活動への投資が含まれます。
地域別動向:北米が市場を独占しており、これはヘルスケア分野への投資増加によるものです。しかし、アジア太平洋地域は、大衆の間で慢性疾患の発生が増加していることから、急成長市場として浮上しています。
競合情勢:ポイントオブケア診断業界の主な市場プレイヤーとしては、アボット・ラボラトリーズ、ベックマン・コールター、ベクトン・ディッキンソン・アンド・カンパニー、F.ホフマン・ラ・ロシュAGなどが挙げられます。これらの企業は研究開発(R&D)に投資し、世界のプレゼンスを拡大し、高度な検査ソリューションの開発に注力しています。
課題と機会:課題には、高精度とコスト効率の高いソリューションの必要性が含まれます。とはいえ、個別化医療の利点に対する意識の高まりにより、これらの課題は克服されると予測されます。
慢性疾患の蔓延
世界保健機関(WHO)によると、慢性疾患とも呼ばれる非感染性疾患によって毎年4,100万人が死亡しており、これは世界全体の死亡者数の74%に相当します。慢性疾患の世界の増加は、POC診断サービスの需要を促進しています。糖尿病、心血管疾患、呼吸器疾患などの慢性疾患は大衆の間でますます蔓延しており、世界中のヘルスケアシステムに大きな課題を突きつけています。POC診断は、これらの健康合併症の自発的な検出と継続的なモニタリングのための貴重なツールを提供し、タイムリーな介入と効果的な疾病管理を促進します。POC検査の利便性と入手の容易さは、特に従来の検査施設へのアクセスが制限されていたり、利用できなかったりする遠隔地や農村部での慢性疾患の管理にさらに貢献します。このように、慢性疾患の有病率の増加が、世界中でPOC検査の需要を牽引しています。
様々な技術的進歩
技術革新と統合は、ポイントオブケア診断薬市場の成長を支える上で重要な役割を果たしています。小型化、バイオセンサー、コネクティビティへの取り組みや調査により、様々なスマートでポータブルな診断機器やシステムが生み出されています。これらのPOC機器は、従来の検査室ベースの方法ではしばしば実現できなかった幅広い検査を高い精度で行うことができます。また、複数の機器を必要とせず、検査結果を得るまでの所要時間を短縮するために、拡張された検査メニューと統合されていることも多いです。
各社はまた、コンパクトなサイズで包括的な検査設備を提供するPOC診断システムの製造も計画しています。市場の主要企業は、ヘルスケア提供に革命を起こすために、ユニークで信頼性の高い診断ソリューションを提供するために、他の企業とも協力しています。モルビオ・ダイアグノスティックスは2023年にSigTuple社との提携を宣言し、多くのルーチン検査や診断検査に対応する次世代のAI対応ポータブル機器を開発します。
個別化医療重視の高まり
大衆の間で個別化医療へのニーズが高まっていることが、市場の成長を後押ししています。米国国立がん研究所(NCI)は、さまざまな新規薬剤の組み合わせによる小児および成人の治療効果を調べるため、大規模な精密医療がんイニシアチブを立ち上げました。
さらに、ヘルスケア部門がより患者中心のアプローチに移行しつつある中、個別化医療の受け入れが患者のニーズに応じた治療計画の作成を促進しています。POC診断薬は、迅速かつ的を絞った診断ソリューションを提供し、正確な疾患の特定とモニタリングを支援するため、この手順において極めて重要な役割を果たしています。POC診断薬は、治療や全般的な健康状態に関して患者に安心感を与えるものであり、これが患者から高い支持を得ている理由でもあります。さらに、コリエル・ライフサイエンス社の調査によると、精密医療は世界の採用の転換期に達していることが確認されています。
The global point-of-care diagnostics market size reached US$ 49.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 99.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. The increasing demand for faster and more convenient diagnostic solutions, rising prevalence of infectious diseases across the globe, and advancements in technology and miniaturization represent some of the key factors driving the market.
Market Growth and Size: The global point-of-care diagnostics market is experiencing moderate growth, on account of the increasing occurrence of various chronic diseases among the masses.
Major Market Drivers: Key factors include the growing development of point-of-care tools and the rising focus on personalized medicine for better patient outcomes.
Key Market Trends: Major trends include investments in research activities to develop advanced testing solutions and portable point-of-care testing systems for providing healthcare services in remote areas.
Geographical Trends: North America dominates the market, driven by rising investments in the healthcare sector. However, Asia Pacific is emerging as a fastest-growing market on account of the rising occurrence of chronic diseases among the masses.
Competitive Landscape: Some of the major market players in the point-of-care diagnostics industry include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, among many others. These companies are investing in research and development (R&D), expanding their global presence, and focusing on the development of advanced testing solutions.
Challenges and Opportunities: Challenges include the need for high accuracy and cost-effective solutions. Nonetheless, the rising awareness about the benefits of personalized medicines is projected to overcome these challenges.
The growing prevalence of chronic diseases
According to the World Health Organization (WHO), non-communicable diseases, also called chronic diseases, kill 41 million people each year, which is equivalent to 74% of all deaths globally. The global rise in chronic diseases is driving the demand for POC diagnostic services. Chronic conditions, such as diabetes, cardiovascular diseases, and respiratory disorders, are becoming increasingly prevalent among the masses, posing substantial challenges to healthcare systems worldwide. POC diagnostics offer a valuable tool for spontaneous detection and continuous monitoring of these health complications, facilitating timely interventions and effective disease management. The convenience and easy availability of POC testing further contribute to the management of chronic diseases, especially in remote or rural areas where access to traditional laboratory facilities is limited or not available. Thus, the growing prevalence of chronic diseases is driving the point-of-care diagnostics demand around the world.
Various technological advancements
Technological innovations and integration play a crucial role in supporting the point-of-care diagnostics market growth. Initiatives and research in miniaturization, biosensors, and connectivity are leading to the creation of various smart and portable diagnostic devices and systems. These POC devices can perform a wide range of tests with high accuracy, which traditional laboratory-based methods often fail to deliver. They are also often integrated with expanded test menus to eliminate the need for multiple devices and reduce turnaround time for getting the test results.
Companies are also planning to produce POC diagnostics systems which are compact in size and offer comprehensive testing facilities. Key market players are also collaborating with other firms to offer unique and reliable diagnostic solutions to revolutionize healthcare delivery. Molbio Diagnostics declared its partnership with SigTuple in 2023 to develop next-generation AI-enabled portable devices for many routine and diagnostic tests.
The growing emphasis on personalized medicine
The increasing need for personalized medicine among the masses is propelling the growth of the market. The National Cancer Institute (NCI) has launched a large precision medicine cancer initiative to examine the effectiveness of treating children and adults with various novel drug combinations.
Moreover, as the healthcare sector is transitioning towards a more patient-centric approach, the acceptance of personalized medicine is facilitating the creation of treatment plans according to the needs of patients. POC diagnostics play a pivotal part in this procedure as it offers rapid and targeted diagnostic solutions that aid in precise disease identification and monitoring. They provide a sense of assurance to patients regarding their treatment and overall wellbeing, which is also responsible for their high acceptance among patients. Moreover, according to research done by Coriell Life Sciences, it is confirmed that precision medicine has reached a global tipping position for adoption.
IMARC Group provides an analysis of the key trends in each segment of the global point-of-care diagnostics market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, platform, prescription mode, and end-user.
Blood-Glucose Monitoring Kit
Cardio-Metabolic Monitoring Kit
Pregnancy and Fertility Testing Kit
Infectious Disease Testing Kit
Cholesterol Test Strip
Hematology Testing Kit
Others
Blood-glucose monitoring kit represents the most popular product type
The report has provided a detailed breakup and analysis of the market based on product type. This includes blood-glucose monitoring kit, cardio-metabolic monitoring kit, pregnancy and fertility testing kit, infectious disease testing kit, cholesterol test strip, hematology testing kit, and others. According to the report, blood-glucose monitoring kit represented the largest segment.
Blood-glucose monitoring kits are designed to be user-friendly, allowing patients to perform tests themselves without the need for specialized medical training. The simplicity and convenience of these kits are contributing to their widespread adoption, making them accessible to a broad spectrum of patients, including those in remote or underserved areas. Moreover, blood-glucose monitoring kits are often compact and portable, enabling patients to carry them wherever they go, thereby offering a favorable point-of-care diagnostics market outlook. Furthermore, on the basis of the predictions and research by the Institute for Health Metrics and Evaluation, global diabetes cases will increase from 529 million to 1.3 billion by 2050. The US Food and Drug Administration cleared the first over-the-counter (OTC) continuous glucose monitoring system (CGM) in the US -- the Dexcom Stelo Glucose Biosensor System. This will help people with Type 2 diabetes who don't need insulin to track their blood sugar for nonmedical purposes.
Lateral Flow Assays
Dipsticks
Microfluidics
Molecular Diagnostics
Immunoassays
Lateral flow assays represent the leading platform
A detailed breakup and analysis of the market based on the platform has also been provided in the report. This includes lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. According to the report, lateral flow assays hold the largest point-of-care diagnostics market share.
Lateral flow assays are known for their "simplicity" and "user-friendly" design. They are easy to use, requiring minimal training for both healthcare professionals and patients. The test procedure typically involves incorporating a samples like blood, saliva, and urine to a test strip, and the results are visually interpreted through the appearance of colored lines, eliminating the need for complex laboratory equipment. They offer stability over a wide range of environmental conditions and have a long shelf life. They also require small sample volume to conduct tests. As a result, various organizations and institutions are investing in the development of advanced lateral flow assays. For example, iiCON announced in 2021 that it will support Liverpool SME to develop advanced lateral flow tests, which can be performed with and without the addition of the Nano Biosols reagent.
Prescription-Based Testing
OTC Testing
Prescription-based testing currently dominates the market
The report has provided a detailed breakup and analysis of the market based on prescription mode. This includes prescription-based testing and OTC testing. According to the report, prescription-based testing represented the largest segment.
Prescription-based testing involves diagnostic tests that require a healthcare professional's order or prescription before they can be performed. These tests often undergo rigorous regulatory approval processes to ensure their safety, efficacy, and accuracy. The involvement of healthcare professionals in prescribing these tests ensures appropriate medical supervision and interpretation of the results, leading to better patient care and treatment decisions. Prescription-based testing is essential for the accurate detection, staging, and monitoring of diseases such as cancer, infectious diseases, cardiovascular disorders, and autoimmune conditions. As per the reports of WHO, over 35 million new cancer cases are predicted in 2050. This will further increase the need for prescription-based testing solutions.
Professional Diagnostic Centers
Home Care
Research Laboratories
Others
Professional diagnostic centers account for the majority of the market share
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes professional diagnostic centers, home care, research laboratories, and others. According to the report, professional diagnostic centers accounted for the largest market share.
Professional diagnostic centers offer a wide range of POC diagnostic tests, catering to various medical specialties and healthcare needs. These centers often have advanced equipment and well-trained personnel, allowing them to perform a diverse set of tests, including blood tests, rapid infectious disease testing, urinalysis, pregnancy tests, and more. The availability of comprehensive testing services makes professional diagnostic centers a preferred choice for both patients and healthcare providers. Moreover, professional diagnostic centers are staffed by qualified healthcare professionals, including medical technologists, clinical laboratory scientists, and physicians.
According to a report by the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the Asia-Pacific Trade and Investment Trends 2022/2023 demonstrates that the pharmaceutical industry attracted the highest amount of FDI ($32 billion) between 2008 to 2021 - significantly more than investments in the medical devices ($20 billion), biotechnology ($17 billion) and healthcare ($10.8 billion) subsectors. This further increased the number of professional diagnostic centers providing comprehensive healthcare services.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America was the largest market for point-of-care diagnostics.
North America boasts a highly developed healthcare infrastructure with well-established medical facilities, laboratories, and diagnostic centers. The robust healthcare system of the region enables widespread adoption and integration of POC diagnostics into routine medical practice, contributing to their market dominance. Besides this, the high prevalence of chronic diseases, such as diabetes, cardiovascular disorders, and respiratory conditions, is driving the demand for comprehensive testing services. POC diagnostics play a crucial role in the early detection, monitoring, and management of these chronic conditions.
As per a press release by the Centers for Disease Control and Prevention, the number of Americans with diabetes will range between 1 in 3 to 1 in 5 by 2050. This will further increase the demand for point-of-care testing solutions in the region.
The competitive landscape of the market is dynamic and characterized by the presence of numerous players, including established companies, emerging startups, and specialized firms and effective in answering queries related to how big is the point-of-care diagnostics market? Major players are heavily investing in R&D to innovate and develop cutting-edge POC diagnostic solutions. They are also focusing on improving the accuracy, sensitivity, and speed of their tests. Top companies are expanding the range of analytes and diseases that can be detected using POC devices. R&D efforts also involve exploring new technologies, such as biosensors, microfluidics, and lab-on-a-chip systems, to enhance the performance of POC diagnostics. They are also tailoring their products and marketing strategies to meet the specific healthcare needs and regulatory requirements of different countries. For example, Cipla launched a point-of-care testing device for various non-communicable diseases and other medical conditions as an addition to its product offerings. The point-of-care diagnostics market statistics indicate a robust expansion trajectory, fueled by rising demands for rapid testing, technological innovation, and a growing emphasis on decentralized healthcare.
Abbott Laboratories
Beckman Coulter, Inc.
Becton Dickinson and Company
F. Hoffmann-La Roche AG
Instrumentation Laboratory
Johnson & Johnson
Nova Biomedical Corporation
Pts Diagnostics
Qiagen
Siemens
Trinity Biotech
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
January 2023: Beckman Coulter, Inc. announced that it has entered a strategic partnership with MeMed to develop and commercialize a host immune response diagnostic test.
January 2023: Becton Dickinson and Company presented educational grant funding towards 19 to Zero for a point-of-care testing pilot in the primary care setting.